Author

Keith S. Kaye

Rutgers, The State University of New JerseyORCID 0000-0003-2051-1732Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:bacteria (other)· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Ahmed Elsheikh· 1 shared Ben Kittleson· 1 shared Carter N. Abbott· 1 shared Cely Saad AbboudiD· 1 shared David S. WeissiD· 1 shared Estefany GarciaiD· 1 shared Fernando G. PasterániD· 1 shared Gauri G. RaoiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Ahmed Elsheikh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyAntimicrobial Agents and ChemotherapyPeer-reviewedDec 19, 2025

A Mechanism Based Pharmacokinetic/Pharmacodynamic Analysis of Polymyxin B-Based Combination Therapy Against Carbapenem-Resistant Klebsiella pneumoniae Isolates with Diverse Phenotypic and Genotypic Resistance Mechanisms

Ramya Mahadevan, Estefany Garcia, Rajnikant Sharma…·Gauri G. Rao

This study develops a mechanism-based pharmacokinetic/pharmacodynamic model to evaluate PMB-based combination therapy against CRKP, showing synergistic effects with lower PMB doses.

5 citations

humanstatistical model

𝕏 PostBluesky

MicrobiologybioRxivPreprintNov 27, 2025

Shift in pre-existing antibiotic heteroresistance explains AST change from susceptible to resistant during patient treatment

Ben Kittleson, Carter N. Abbott, Keith S. Kaye, David S. Weiss

The paper shows that a shift in pre-existing antibiotic heteroresistance, not de novo mutation, explains a change from susceptible to resistant classification during treatment.

DOI 10.1101/2025.11.27.690971

bacteria (other)experimental assay

𝕏 PostBluesky